Abstract 1670
Background
International recommendations for cancer control support the organization of breast cancer care with a multidisciplinary approach in Breast Units (BU). The BU of the Catalan Institute of Oncology (ICO) is a functional unit for breast cancer with oncologists, gynecologists, surgeons and cancer nurses specialized in for diagnosis, treatment and monitoring breast cancer patients. Pathologists and radiologists are also working with the BU. Several international guidelines include nurse as essential part of BU and defined their model of care, management and functions.
The objective is to describe care nurse model and activity of the Breast Unit in a cancer center.
Methods
Retrospective cross-sectional study. Population cancer patients attended at the BU of the ICO during 2016 to 2017 were included. Variables collected were socio-demographic, clinical - pathology and treatment and nursing interventions for patients. Data was extracted from the clinical record. Data analysis was descriptive using the statistical package SPSS v15.
Results
Total of 382 patients. Nursing interventions in patients with early stage breast cancer were: 321 (98.85%) visits before the start of treatments; 322 (99.1%) visits during treatments; 230 (70.8%) visits after finishing treatments; 319 (98.2%) coordination activities for the continuity of care and 136 (14.8%) consultations and derivations to professionals of other services.
Nursing interventions in patients with advanced stage breast cancer: 32 (56.1%) visits before the start of treatments; 33 (57.9%) visits during treatments; 17 (29.8%) coordination activities for the continuity of care; and 12 (21.8%) consultations and derivations to professionals of other services.
Conclusions
According to this multidisciplinary model of care, patients with breast cancer in the early stages have a high level of clinical contacts with the nurse along the cancer care process. However, there is a high percentage of patients with advanced disease that could not benefit from an early and continued access to nurse.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Generalitat of Catalonia, Department of Health.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3842 - Effect of docetaxel-resistance on the reactivity of prostate cancer cells to metformin
Presenter: Jessica Catapano
Session: Poster Display session 3
Resources:
Abstract
5198 - Cell plasticity and taxanes resistance in metastatic prostate cancer: ESRP1 as a predictive biomarker of taxane response
Presenter: Natalia Jimenez
Session: Poster Display session 3
Resources:
Abstract
2981 - Effect of Selumetinib plus AZD8186 treatment on Cabazitaxel sensitivity in docetaxel-acquired resistant metastatic prostate cancer cell lines
Presenter: Vicenc Ruiz de Porras
Session: Poster Display session 3
Resources:
Abstract
2779 - Anti-tumor activity of cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, in pancreatic ductal adenocarcinoma cells
Presenter: Majid Momeny
Session: Poster Display session 3
Resources:
Abstract
1782 - The molecular mechanisms of EpCAM in regulating tumor progression and development of anti-EpCAM antibodies for colon cancer diagnosis and therapy
Presenter: Han-chung Wu
Session: Poster Display session 3
Resources:
Abstract
1322 - Detection of microRNAs as biomarker for anti-EGFR antibody resistance in colon cancer patients
Presenter: Jens Hahne
Session: Poster Display session 3
Resources:
Abstract
1579 - Serum exosomal microRNA-199b-5p as a novel circulating biomarker to predict response of preoperative chemoradiotherapy for locally advanced rectal cancer
Presenter: Dong Won Baek
Session: Poster Display session 3
Resources:
Abstract
1761 - Live biobank of patient-derived organoids from Thai colorectal cancer patients enables clinical outcome prediction
Presenter: Pariyada Tanjak
Session: Poster Display session 3
Resources:
Abstract
3542 - The biological implications of PDCD6 dysregulation in colorectal cancer
Presenter: Romina Briffa
Session: Poster Display session 3
Resources:
Abstract
4634 - Comparative molecular analyses between microsatellite stable BRAFV600E mutant colorectal cancers and BRAFV600E mutant melanomas.
Presenter: Mohamed Salem
Session: Poster Display session 3
Resources:
Abstract